- Home
- AQST vs XMAX Comparison
AQST vs XMAX Comparison
Compare AQST & XMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.08
N/A
Current Price
$8.65
Company Overview
Basic Information| Metric | AQST | XMAX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 534.9M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | AQST | XMAX |
|---|---|---|
| Price | $4.08 | $8.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | $10.08 | N/A |
| Revenue Next Year | $49.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.94 | $8.10 |
| 52 Week High | $7.55 | $9.31 |
Technical Indicators
Market Signals| Indicator | AQST | XMAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 59.79 |
| Support Level | $3.84 | $8.45 |
| Resistance Level | $4.38 | $9.31 |
| Average True Range (ATR) | 0.24 | 0.39 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 8.47 | 45.45 |
Price Performance
Historical Comparison AQST
XMAX
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.